Iterum Therapeutics Analyst Remains Bullish Despite Concerns Over FDA Letter
A lack of clarity and final decision in the U.S. Food and Drug Administration's (FDA) recent letter to Iterum Therapeutics PLC (NASDAQ: ITRM) failed to deter H.C. Wainwright & Co’s bullish sentiment on Iterum stock.